Advertisement

Collagenase in Europe from the Experimental Phase to Practical Use

  • José M. Arandes-Renú
  • Rafael Sanjuán-Cerveró
  • Ignacio Moya-Molinas
Chapter

Abstract

The use of enzymatic fasciotomy with clostridium histolyticum collagenase for the management of Dupuytren’s contracture has progressively increased since its approval for clinical use. The main reason for that is the fact that it is a non-invasive, safe, effective and quick procedure.

A systematic search was performed combining the following keywords: ‘Dupuytren disease’ and ‘collagenase’ and ‘clostridium histolyticum’. One hundred fifty-nine studies published by European authors were selected. Many papers were rejected for not reporting the results of the treatment.

Treatment with clostridium histolyticum collagenase provides good results in Dupuytren’s contracture, especially in the metacarpal phalangeal joints. In addition to that, it is cost-effective.

The advantages of the procedure are the short recovery period and the low incidence of severe adverse effects. The patients’ satisfaction level is generally high.

The majority of studies do not use subjective valuation systems; they have short follow-up periods and do not follow the consensus criteria to define recurrences. However, their results are usually similar to those of the clinical trials.

Notes

Disclosure Statement

We declare that co-authors JMAR and RSC have received honoraria and travel expenses for advisory board work with Pfizer and Sobi. The authors have no conflicts of interest relevant to this work.

References

  1. 1.
    Lengenmann P. Unblutige Behandlung der Dupuytrenschen Fingerkontraktur. Dtsch Med Wochenschr. 1903;29(23):407–8.CrossRefGoogle Scholar
  2. 2.
    Ssadikow WS. Über ein neues Kollagen-lösendes Ferment (Kollagenase). Biochem Z. 1927;181:267–83.Google Scholar
  3. 3.
    Badalamente MA, Hurst LC. Enzyme injection as nonsurgical treatment of Dupuytren’s disease. J Hand Surg Am. 2000;25(4):629–36.PubMedCrossRefGoogle Scholar
  4. 4.
    Witthaut J, Jones G, Skrepnik N, et al. Efficacy and safety of collagenase clostridiumn histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies. J Hand Surg Am. 2013;38(1):2–11.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Warwick D, Arner M, Pajardi G, et al. Collagenase clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes. J Hand Surg Eur. 2015;40(2):124–32.CrossRefGoogle Scholar
  6. 6.
    Peimer CA, Blazar P, Coleman S, et al. Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS [collagenase options for reduction of Dupuytren long-term evaluation of safety study]): 5-year data. J Hand Surg Am. 2015;40(8):1597–605.PubMedCrossRefGoogle Scholar
  7. 7.
    Bebbington E, Furniss D. Linear regression analysis of hospital episode statistics predicts a large increase in demand for elective hand surgery in England. J Plast Reconstr Aesthet Surg. 2015;68(2):243–51.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Wilbrand S, Pajardi G, Parolo C. Collagenase. In: Warwick DJ, editor. Dupuytren’s disease. FESSH instructional course 2015. Torino: Ed Edizioni Medico-Scientifiche; 2015. p. 135–48.Google Scholar
  9. 9.
    Marks M, Krefter C, Herren DB. Behandlungsmethoden bei Patienten mit Morbus Dupuytren in der Schweiz. Treatment methods for patients with Dupuytren’s disease in Switzerland. Handchir Mikrochir Plast Chir. 2016;48(3):155–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Liberati A, Altman DJ, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.  https://doi.org/10.1371/journal.pmed.1000100.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ball C, Pratt AL, Nanchahal J. Optimal functional outcome measures for assessing treatment for Dupuytren’s disease: a systematic review and recommendations for future practice. BMC Musculoskelet Disord. 2013;14:131. www.biomedcentral.com/1471-2474/14/131 PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Brazzelli M, Cruickshank M, Tassie E, et al. Collagenase clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation. Health Technol Assess. 2015;19(90):1–201.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Cobo-Molinos J, Cobo-Molinos A. Effectiveness collagenase injection in the treatment of patients with Dupuytren systematic review. J Trauma Treat. 2016;5(5):343.  https://doi.org/10.4172/2167-1222.1000343.CrossRefGoogle Scholar
  14. 14.
    Degreef I. Collagenase treatment in Dupuytren contractures: a review of the current state versus future needs. Rheumatol Ther. 2016;3(1):43–51.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Lindau T, Armstrong D, Azzopardi E, et al. Collagenase in Dupuytren’s disease: a review of the literature and suggested clinical use. J Clin Rheumatol Musculoskelet Med. 2012;3(1):37–46.Google Scholar
  16. 16.
    Sanjuán-Cerveró R, Carrera Hueso FJ, Vázquez Ferreiro P, et al. Adverse effects of collagenase in the treatment of Dupuytren disease: a systematic review. BioDrugs. 2017;31(2):105–15.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Sanjuán-Cerveró R, Carrera-Hueso FJ, Vázquez-Ferreiro P, et al. Efficacy and adverse effects of using collagenase in the treatment of Dupuytren’s disease. A meta-analysis. Bone Joint J Br. 2018;100:73–80.Google Scholar
  18. 18.
    Smeraglia F, del Buono A, Maffulli N. Collagenase clostridium histolyticum in Dupuytren’s contracture: a systematic review. Br Med Bull. 2016;118(1):149–58.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Syed AM, McFarlane J, Chester T, et al. Clinical efficacy and cost effectiveness of clostridium histolyticum collagenease injections in a subpopulation of patient with moderate Dupuytren’s contracture. Eur Orthop Traumatol. 2014;5(3):311–6.CrossRefGoogle Scholar
  20. 20.
    Thomas A, Bayat A. The emerging role of clostridium histolyticum collagenase in the treatment of Dupuytren disease. Ther Clin Risk Manag. 2010;6:557–72.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Warwick D, Arandes-Renú JM, Pajardi G, et al. Collagenase clostridium histolyticum: emerging practice patterns and treatment advances. J Plast Surg Hand Surg. 2016;50(5):251–61.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Syed F, Thomas AN, Singh S, et al. In vitro study of novel collagenase (XIAFLEX®) on Dupuytren’s disease fibroblast displays unique drug related properties. PLoS One. 2012;7(2):e31430:1–22.CrossRefGoogle Scholar
  23. 23.
    Del Carlo M, Cole AA, Hart SGE, et al. Comparative analysis of collagen degradation in Peyronie’s disease plaque and Dupuytren’s contracture cord tissues injected with mixed collagenase subtypes. AUA Annual Meeting Program Abstracts, Chicago, Illinois. J Urol. 2009;181(Suppl 4):279.CrossRefGoogle Scholar
  24. 24.
    Sanjuán-Cerveró R, Gómez-Herrero D, Carrera-Hueso FJ. Mechanism of action of collagenase clostridium histolyticum for clinical application. Eur J Clin Pharm. 2016;18(4):263–72.Google Scholar
  25. 25.
    Warwick D. Collagenase: what we may never know (a discussion). In: Werker PMN, Dias J, Eaton C, et al., editors. Dupuytren disease and related diseases. The cutting edge. Cham: Springer; 2017. p. 145–9.CrossRefGoogle Scholar
  26. 26.
    Kjaersgaard-Andersen P. Collagenase injections improved function in patients with Dupuytren’s contractures. Orthop Today Eur. 2011;14:11.Google Scholar
  27. 27.
    Leclère FM, Mathys L, Vögelin E. Traitement de la maladie de Dupuytren par collagénase injectable, évaluation de l’échographie assistée. Chir Main. 2014;33(3):196–203.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Spanholtz TA, Holzbach T, Wallmichrath J, et al. Die Behandlung des Dupuytren’schen Kontraktur mittels Kollagenase-Erste Klinische Erfahrungen. Treatment of Dupuytren’s contracture by means of injectable collagenase: first clinical experiences. Handchir Mikrochir Plast Chir. 2011;43(5):275–80.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Pajardi G, Parolo C, Cavalli E, et al. Collagenasi: report preliminare. Chir Mano. 2013;50(1):43–7.Google Scholar
  30. 30.
    Considine S, Heaney R, Hirpara KM. Early results of the use of collagenase in the treatment of Dupuytren’s contracture. Ir J Med Sci. 2015;184(2):323–7.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Mosetto F, Kontou E, Borrione S, et al. Trattamento del morbo di Dupuytren con collagenasi–Xiapex®: problematiche organizzative e gestionali nell’ASL TO4, ospedale di Ivrea. Chir Mano. 2016;53(2):12–5.Google Scholar
  32. 32.
    Knobloch K, Kraemer R, Papst S, et al. German version of the brief Michigan hand outcomes questionnaire: implications for early quality of life following collagenase injection in Dupuytren contracture. Plast Reconstr Surg. 2012;129(5):886e–7e.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Knobloch K, Kühn M, Sorg H, et al. German version of the Unité Rhumatologique des Affections de la Main (URAM) scale in Dupuytren’s disease: the need for a uniform definition of recurrence. Comment on the article by Beaudreil J, Allard A, Zerkak D, et al. Arthritis Care Res. 2012;64(5):793.CrossRefGoogle Scholar
  34. 34.
    Atroshi I, Strandberg E, Lauritzson A, et al. Costs for collagenase injections compared with fasciectomy in the treatment of Dupuytren’s contracture: a retrospective cohort study. BMJ Open. 2014;4(1):e004166.  https://doi.org/10.1136/bmjopen-2013-004166.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Atroshi I, Nordenskjöld J, Lauritzson A, et al. Collagenase treatment of Dupuytren’s contracture using a modified injection method: a prospective cohort study of skin tears in 164 hands, including short-term outcome. Acta Orthop. 2015;86(3):310–5.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Pérez-Giner RA, Aguilella L. Resultado precoz del tratamiento de la enfermedad de Dupuytren mediante inyección de colagenasa. Rev Iberamer Cir Mano. 2015;43(1):13–9.CrossRefGoogle Scholar
  37. 37.
    Lauritzon A, Atroshi I. Collagenase injections for Dupuytren’s disease: prospective cohort study assessing 2-year treatment effect durability. BMJ Open. 2017;7:e012943.  https://doi.org/10.1136/bnjopen-2016-012943.CrossRefGoogle Scholar
  38. 38.
    Warwick D. Dupuytren’s disease: my personal view. J Hand Surg Eur. 2017;42(7):665–72.CrossRefGoogle Scholar
  39. 39.
    Alentorn-Geli E, Piñol I, Valverde D, et al. Infiltració de col·lagenasa de clostridium hystoliticum per al tractament de la malaltia de Dupuytren: resultats preliminars. Rev Cir Ortop Traumatol. 2012;3:19–23.Google Scholar
  40. 40.
    Vollbach FH, Walle L, Fansa H. Morbus Dupuytren—Patientenzufriedenheit und funktionelle Ergebnisse ein Jahr nach partieller Aponeurektomie und Injection von Kollagenase. Dupuytren’s disease–patient satisfaction and functional results one year after partial fasciectomy and injection of collagenase. Handchir Mikrochir Plast Chir. 2013;45(5):258–64.PubMedCrossRefGoogle Scholar
  41. 41.
    Mármol-Soler S, Espejo-Ortega L, Gutiérrez-Ortega C, et al. Tratamiento no quirúrgico de la contractura de Dupuytren con colagenasa de clostridium hystoliticum. Cir Plast Iberolatinoam. 2013;39(3):247–54.CrossRefGoogle Scholar
  42. 42.
    Martín-Ferrero MA, Simón-Pérez C, Rodríguez-Mateos JI, et al. Tratamiento de la enfermedad de Dupuytren mediante la colagenasa del clostridium histolyticum. Rev Esp Cir Ortop Traumatol. 2013;57(6):398–402.PubMedGoogle Scholar
  43. 43.
    Sanjuán-Cerveró R, Franco-Ferrando N, Poquet-Jornet J. Use of resources and cost associated with the treatment of Dupuytren’s contracture at an orthopedics and traumatology surgery Department in Denia (Spain): collagenase clostridium hystoliticum versus subtotal fasciectomy. BMC Musculoskelet Disord. 2013;14:293. http://www.biomedcentral.com/1471-2474/14/293 PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Alberton F, Corain M, Garofano A, et al. Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren contracture: report of 40 cases. Musculoskelet Surg. 2014;98(3):225–32.PubMedCrossRefGoogle Scholar
  45. 45.
    Binter A, Neuwirth M, Rab M. Behandlung der Dupuytren’schen Kontraktur mit Kollagenase–Ein-Jahres-Follow-up-Analyse anhand von 37 Patienten. Treatment of Dupuytren’s disease with collagenase–a 1-year follow-up of 37 patients. Handchir Mikrochir Plast Chir. 2014;46(6):355–60.PubMedGoogle Scholar
  46. 46.
    García-Olea A, Dudley AF, Gimeno-Andrade MD, et al. Efectividad del tratamiento de la enfermedad de Dupuytren (ED) mediante fasciotomía enzimática con colagenasa. Estudio multicéntrico cohortes prospectivo. Rev Iberamer Cir Mano. 2014;42(2):97–106.CrossRefGoogle Scholar
  47. 47.
    Povlsen B, Povlsen SD. What is the better treatment for single digit Dupuytren’s contracture: surgical release or collagenase clostridium histolyticum (Xiapex) injection? Hand Surg. 2014;19(3):389–92.PubMedCrossRefGoogle Scholar
  48. 48.
    Manning CJ, Delaney R, Hayton MJ. Efficacy and tolerability of day 2 manipulation and local anaesthesia after collagenase injection in patients with Dupuytren’s contracture. J Hand Surg Eur. 2014;39(5):466–71.CrossRefGoogle Scholar
  49. 49.
    Zhou C, Hovius SF, Slijper HP, et al. Collagenase clostridium histolyticum versus limited fasciectomy for Dupuytren’s contracture: outcomes from a multicenter propensity-score matched study. Plast Reconstr Surg. 2015;136(1):87–97.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Haerle M, Witthaut J, Giunta R, et al. Treatment of Dupuytren’s contracture with collagenase clostridium histolyticum under clinical practice conditions: ReDUCTO study. Behandlung des Morbus Dupuytren mit mikrobieller Kollagenase aus clostridium histolyticum unter Bedingungen der Klinischen Praxis ReDUCTO-Studie. GMS Ger Plast Reconstr Aesthet Surg. 2015;5:Doc 06.  https://doi.org/10.3205/gpras000034.CrossRefGoogle Scholar
  51. 51.
    Strömberg J, Ibsen-Sörensen A, Fridén J. Comparison of treatment outcome after collagenase and needle fasciotomy for Dupuytren contracture: a randomized, single-blinded, clinical trial with a 1-year follow-up. J Hand Surg Am. 2016;41(9):873–80.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Odinsson A, Brenne LE, Lurie TB, et al. Dupuytren’s contracture. The safety and efficacy of collagenase treatment. J Hand Surg Asian Pac Vol. 2016;21(2):187–92.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Arora R, Kaiser P, Kastenberger TJ, et al. Injectable collagenase clostridium histolyticum as a nonsurgical treatment for Dupuytren’s disease. Oper Orthop Traumatol. 2016;28(1):30–7.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Verstreken F, Degreef I, Decramer A, et al. Effectiveness and safety of collagesase clostridium histolyticum in Dupuytren’s disease: an observational study in Belgium. Acta Orthop Belg. 2016;82(2):405–12.Google Scholar
  55. 55.
    Scherman P, Jenmaln P, Dahlin LB. One-year results of needle fasciotomy and collagenase injection in treatment of Dupuytren’s contracture: a two-centre prospective randomized clinical trial. J Hand Surg Eur. 2016;41(6):577–82.CrossRefGoogle Scholar
  56. 56.
    De Filippo G, Sauda R, Galli S, et al. Efficacia e sicurezza delle iniezioni di collagenasi di clostridium histolyticum per le deformità in flessione nella malattia di Dupuytren: risultati a breve termine. Chir Mano. 2016;53(2):20–6.Google Scholar
  57. 57.
    De Mas A, Impagnatiello M, Udali G, et al. Trattamento della contrattura di Dupuytren con la CCH: i risultati del P.O. di Santa Maria degli Angeli (PN). Chir Mano. 2016;53(2):4–11.Google Scholar
  58. 58.
    Pajardi G, Adani R, Bassetto F, et al. The use of collagenase clostridium histolyticum in the Dupuytren’s contracture: the italian compassionate-use program-expanded access. Chir Mano. 2016;53(3):42–52.Google Scholar
  59. 59.
    Pajardi G, Parolo C, Baga L. Efficacy of collagenase clostridium histolyticum injection in moderate and severe Dupuytren contracture: retrospective analysis of results in 682 italian patients. Chir Mano. 2016;53(4):33–43.Google Scholar
  60. 60.
    Passaretti U, Lanni G. L’esperienza dell’ospedale dei Pellegrini di Napoli nel trattamento della malattia di Dupuytren con collagenasi. Chir Mano. 2016;53(2):16–9.Google Scholar
  61. 61.
    Murphy LE, Murphy KM, Kilpatrick SM, et al. The use of collagenase clostridium histolyticum in the management of Dupuytren’s contracture—outcomes of a pilot study in a district general hospital setting. Ulster Med J. 2017;86(2):94–8.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Hansen KL, Werlinrud JC, Larsen S, et al. Difference in success treating proximal interphalangeal and metacarpophalangeal joints with collagenase: results of 208 treatments. Plast Reconstr Surg Glob Open. 2017;5(4):e1275.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Keller M, Arora R, Schmiedle G, et al. Therapie des Morbus Dupuytren mit Kollagenase clostridium histolyticum. Orthopade. 2017;46(4):321–7.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Skov ST, Bisgaard T, Søndergaard P, et al. Injectable collagenase versus percutaneous needle fasciotomy for Dupuytren contracture in proximal interphalangeal joint: a randomized controlled trial. J Hand Surg Am. 2017;42(5):321–8.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Baur EM. Minimally invasive treatment of Dupuytren contracture: collagenase versus PNF. In: Werker PMN, Dias J, Eaton C, et al., editors. Dupuytren disease and related diseases. The cutting edge. Cham: Springer; 2017. p. 251–8.CrossRefGoogle Scholar
  66. 66.
    Hupez A, Detrembleur C, van Innis F, et al. Comparative study of collagenase injection versus fasciectomy in Dupuytren’s contracture: a 1-year follow-up. Louvain Med. 2017;136(4):231–7.Google Scholar
  67. 67.
    Pototschnig A, Volkmer E, Giunta RE. Therapie des Morbus Dupuytren mit injektion von Kollagenase in Deutschland—Ergebnisse und Komplikationen na 110 Gelenken. Treatment of Dupuytren’s disease with collagenase injections in Germany: efficacy and adverse effects in 110 treated joints. Handchir Mikrochir Plast Chir. 2017;49(3):154–61.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    van Beeck A, van den Broek M, Michielsen M, et al. Efficacy and safety of collagesase treatment for Dupuytren’s disease: 2-year follow-up results. Hand Surg Rehab. 2017;36(5):346–9.CrossRefGoogle Scholar
  69. 69.
    Fischer LM, Dahmann S, Simunec D, et al. Collagenase injections for the treatment of single cords in cases of Dupuytren’s contracture–a prospective intervention study of long-term experience with Xiapex®. GMS Ger Plast Reconstr Aesthet Surg. 2017;7:1–8. http://www.egms.de/en/journals/gpras/2017-7/gpras000047.shtml Google Scholar
  70. 70.
    Verheyden JR. Early outcomes of a sequential series of 144 patients with Dupuytren’s contracture treated by collagenase injection using an increased dose, multicord technique. J Hand Surg Eur. 2015;40(2):133–40.CrossRefGoogle Scholar
  71. 71.
    Gosset J. Anatomie des aponévroses palmo-digitales. In: Tubiana R, Hueston JT, editors. La maladie de Dupuytren. Monographie du GEM. Paris: Expansion Scientifique Française; 1986. p. 20–31.Google Scholar
  72. 72.
    Arandes-Renú JM. Enfermedad de Dupuytren. Springer experience & drug review. Madrid: Springer Healthcare Ibérica SL; 2016. p. 9–10.Google Scholar
  73. 73.
    Hayton MJ, Bayat A, Chapman DS, et al. Isolated and spontaneous correction of proximal interphalangeal joint contractures in Dupuytren’s disease: an exploratory analysis of the efficacy and safety of collagenase clostridium histolyticum. Clin Drug Investig. 2013;33(12):905–12.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Bainbridge C, Boyce DE, Gerber R, et al. Efficacité et tolerance de la collagenase de clostridium histolyticum (CCH) chez des patients européens ayant un flessun de Dupuytren: résutats d’une étude ouverte, multicentrique. Chir Main. 2011;30(6):437–8.CrossRefGoogle Scholar
  75. 75.
    McFarlane J, Syed AM, Sibly TF. A single injection of collagenase clostridium histolyticum for the treatment of moderate Dupuytren’s contracture: a 2 year follow-up of 47 patients. J Hand Surg Eur. 2016;41(6):664–8.CrossRefGoogle Scholar
  76. 76.
    Gaston RG, Larsen SE, Pess GM, et al. The efficacy and safety of concurrent collagenase clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: a prospective, multicenter study. J Hand Surg Am. 2015;40(10):1963–71.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Coleman S, Gilpin D, Tursi J, et al. Multiple concurrent collagenase clostridium histolyticum injections to Dupuytren’s cords: an exploratory study. BMC Musculoskelet Disord. 2012;13:61. www.biomedcentral.com/1471-2474/13/61 PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Coleman S, Gilpin D, Kaplan TD, et al. Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am. 2014;39(1):57–64.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Auxilium Pharmaceuticals Inc. Xiaflex (collagenase clostridium histolyticum) [prescribing information]. Chesterbrook: Auxilium Pharmaceuticals, Inc.; 2014. From http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM208737.pdf.
  80. 80.
    Dahlin LB, Bainbridge C, Leclercq C, et al. Dupuytren’s disease presentation, referral pathways and resource utilisation in Europe: regional analysis of a surgeon survey and patient chart review. Int J Clin Pract. 2013;67(3):261–70.PubMedCrossRefGoogle Scholar
  81. 81.
    Lanting R, Nooraee N, Werker PMN, et al. Patterns of Dupuytren’s disease in fingers: studing correlations with a multivariate ordinal logit model. Plast Reconstr Surg. 2014;134(3):483–90.PubMedCrossRefGoogle Scholar
  82. 82.
    Gilpin D, Coleman S, Hall S, et al. Injectable collagenasa clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am. 2010;35(12):2027.e1–38.e1.CrossRefGoogle Scholar
  83. 83.
    Hurst LC, Badalamente MA, Hentz VR, CORD I Study Group, et al. Injectable collagenase clostridium histololyticum for Dupuytren’s contracture. N Engl J Med. 2009;361(10):968–79.CrossRefPubMedGoogle Scholar
  84. 84.
    Badalamente MA, Hurst LC, Gaston RG, et al. Prospective multicenter, multinational study to evaluate the safety and efficacy of concurrent collagenase clostridium histolyticum injection to treat two Dupuytren contractures in the same hand. In: Werker PMN, Dias J, Eaton C, et al., editors. Dupuytren disease and related diseases. The cutting edge. Cham: Springer; 2017. p. 141–4.CrossRefGoogle Scholar
  85. 85.
    Hurst LC, Badalamente MA, Kulovitz K, et al. Collagenase injection: journey from bench to current advanced clinical use. In: Werker PMN, Dias J, Eaton C, et al., editors. Dupuytren disease and related diseases. The cutting edge. Cham: Springer; 2017. p. 115–25.CrossRefGoogle Scholar
  86. 86.
    Foissac R, Camuzard O, Dumas P, et al. Traitement des brides de la maladie de Dupuytren par la collagénase injectable. Chir Main. 2013;32(4):199–205.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Hoang P. Dupuytren’s contracture treated by collagenase. About a serie of 110 patients. Hand Surg Rehabil. 2016;35(6):451.CrossRefGoogle Scholar
  88. 88.
    Lozi C, Masmejean E. Évaluation de la collagénase de clostridium histolyticum dans le traitement de la maladie de Dupuytren. Étude prospective sur quinze patients. Chir Main. 2013;32(6):472.CrossRefGoogle Scholar
  89. 89.
    Nordenskjöld J, Ahlgren E, Waldau J, et al. Efficacy of using local anesthesia before collagenase injection in reducing overall pain experience in patients treated for Dupuytren contracture: a quasi-randomized study. In: Werker PMN, Dias J, Eaton C, et al., editors. Dupuytren disease and related diseases. The cutting edge. Cham: Springer; 2017. p. 127–9.CrossRefGoogle Scholar
  90. 90.
    Nordenskjöld J, Waldén M, Kjellin A, et al. Benefit of local anesthesia in reducing pain during collagenase injection for Dupuytren’s contracture. Plast Reconstr Surg. 2017;140(3):565–9.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Peimer CA, Blazar P, Coleman S, et al. Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS study): 3-year data. J Hand Surg Am. 2013;38(1):12–22.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Gallagher EJ, Liebman M, Bijur PE. Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med. 2001;38(6):633–8.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Todd KH, Funk KG, Funk JP, et al. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996;27(4):485–9.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Sanjuán-Cerveró R, Carrera-Hueso FJ, Vázquez-Ferreiro P, et al. Pain associated with treatment of Dupuytren contracture with collagenease clostridium histolyticum. J Hand Surg Am. 2017;42(2):e109–14.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Strömberg J, Vanek P, Fridén J, et al. Ultrasonographic examination of the ruptured cord after collagenase treatment of needle fasciotomy for Dupuytren’s contracture. J Hand Surg Eur. 2017;42(7):683–8.CrossRefGoogle Scholar
  96. 96.
    Crivello KM, Potter HG, Moon ES, et al. Does collagenase injection disrupt or digest the Dupuytren’s cord: a magnetic resonance imaging study. J Hand Surg Eur. 2016;41(6):614–20.CrossRefGoogle Scholar
  97. 97.
    Warwick DJ, Graham D, Worsley P. New insights into the immediate outcome of collagenase injections for Dupuytren’s contracture. J Hand Surg Eur. 2016;41(6):583–8.CrossRefGoogle Scholar
  98. 98.
    Pess GM. Effect of delayed finger extension on the efficacy and safety of collagenase clostridium histoliticum treatment for Dupuytren contracture. In: Werker PMN, Dias J, Eaton C, et al., editors. Dupuytren disease and related diseases. The cutting edge. Cham: Springer; 2017. p. 131–6.CrossRefGoogle Scholar
  99. 99.
    Sanjuán-Cerveró R, Franco N. Vasospasm after collagenase clostridium histolyticum infiltration in Dupuytren’s contracture. Int J Med Pharm Case Reports. 2014;1(2):42–8.CrossRefGoogle Scholar
  100. 100.
    Considine S, Hirpara KM. Early results of the use of collagenase in the treatment of Dupuytren’s contracture. Ir J Med Sci. 2013;182(Suppl 2):S52–3.  https://doi.org/10.1007/s11845-014-111-6 Google Scholar
  101. 101.
    Kaplan FT, Badalamente MA, Hurst LC, Merrell GA, Pahk R. Delayed manipulation after collagenase clostridium histolyticum injection for Dupuytren contracture. Hand (N Y). 2015;10(3):578–82.CrossRefGoogle Scholar
  102. 102.
    Mickelson DT, Noland SS, Watt AJ, Kollitz KM, Vedder NB, Huang JI. Prospective randomized controlled trial comparing 1- versus 7-day manipulation following collagenase injection for Dupuytren contracture. J Hand Surg Am. 2014;39(10):1933–41.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
  104. 104.
    Bendon CL, Giele HP. Collagenase for Dupuytren’s disease of the thumb. J Bone Joint Surg Br. 2012;94(10):1390–2.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Costas B, Coleman S, Kaufman G, et al. A randomized phase 2A, double-blind placebo-controled, dose-ranging study to evaluate the safety and effectiveness of collagenase clostridium histolyticum in the treatment of Dupuytren disease nodules. J Hand Surg Am. 2016;41(9):S31.CrossRefGoogle Scholar
  106. 106.
    Costas B, Coleman S, Kaufman G, et al. Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomized controlled trial. BMC Musculoskelet Disord. 2017;18:374.  https://doi.org/10.1186/s12891-017-1713-z.CrossRefPubMedPubMedCentralGoogle Scholar
  107. 107.
    Bainbridge C, Gerber RA, Szczypa P, et al. Efficacy and safety of collagenase clostridium histolyticum (CCH) in patients who had previous hand surgery. J Hand Surg Eur. 2011;36(Suppl 1):S61.Google Scholar
  108. 108.
    Bainbridge C, Gerber RA, Szczypa PP, et al. Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren’s contracture. J Plast Surg Hand Surg. 2012;46(3–4):177–83.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Bradley J, Warwick D. Patient satisfaction with collagenase. J Hand Surg Am. 2016;41(6):689–97.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Hay DC, Louie DL, Earp BE, et al. Surgical finding in the treatment of Dupuytren’s disease after initial treatment with clostridial collagenase (Xiaflex). J Hand Surg Eur. 2014;39(5):463–5.CrossRefGoogle Scholar
  111. 111.
    Sanjuán-Cerveró R, Vaquero M, Carrera-Hueso FJ. Re: Salvage palmar fasciectomy after initial treatment with collagenase clostridium histolyticum. Plast Reconstr Surg. 2016;137(4):760e–1e.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Hurst L. Dupuytren’s contracture. In: Wolfe SW, Hotchkiss RN, Pederson WC, et al., editors. Green’s operative hand surgery, vol. 1. 6th ed. Philadelphia: Churchill Livingstone; 2011. p. 141–58.CrossRefGoogle Scholar
  113. 113.
    Skirven TM, Bachoura A, Jacoby SM, et al. The effect of a therapy protocol for increasing correction of severely contracted proximal interphalangeal joints caused by Dupuytren disease and treated with collagenase injection. J Hand Surg Am. 2013;38(4):684–9.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Collis J, Collocott S, Hing W, et al. The effect of night extension orthoses following surgical release of Dupuytren contracture: a single-center, randomized, controlled trial. J Hand Surg Am. 2013;38(7):1285–94.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Jerosch-Herold C, Shepstone L, Chojnowski AJ, et al. Night-time splinting after fasciectomy or dermo-fasciectomy for Dupuytren’s contracture: a pragmatic, multi-centre, randomised controlled trial. BMC Musculoskelet Disord. 2011;12:136.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Larson D, Jerosch-Herold C. Clinical effectiveness of post-operative splinting after surgical release of Dupuytren’s contracture: a systematic review. BMC Musculoskelet Disord. 2008;9:104.  https://doi.org/10.1186/1471-2474-9-104.CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Sampson SP, Badalamente MA, Hurst LC, et al. The use of a passive motion machine in the postoperative rehabilitation of Dupuytren’s disease. J Hand Surg Am. 1992;17(2):333–8.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Kemler MA, Houpt P, van der Horst CM. A pilot study assessing the effectiveness of postoperative splinting after limited fasciectomy for Dupuytren’s disease. J Hand Surg Eur. 2012;37(8):733–7.CrossRefGoogle Scholar
  119. 119.
    Corain M, Sartore R, Adani R. The use of dynamic dorsal splint for Dupuytren rehabilitation after collagenase injection. In: Werker PMN, Dias J, Eaton C, et al., editors. Dupuytren disease and related diseases. The cutting edge. Cham: Springer; 2017. p. 137–40.CrossRefGoogle Scholar
  120. 120.
    Puntaroni FZ, Lazzerini A. Utilizzo di un nuovo tutore nel trattamento con collagenasi da clostridium histolyticum per la malattia di Dupuytren. Chir Mano. 2016;53(2):69–73.Google Scholar
  121. 121.
    Borelli PP. Aspetti di riabilitazione nel trattamento della malattia di Dupuytren con iniezione di collagenasi di clostridium hitolyticum. Chir Mano. 2016;53(2):54–68.Google Scholar
  122. 122.
    Azouz S, Biswas A, Smith A. Preliminary soft-tissue distraction with the Digit Widget™ in the management of advanced Dupuytren contracture at the proximal interphalangeal joint. In: Werker PMN, Dias J, Eaton C, et al., editors. Dupuytren disease and related diseases. The cutting edge. Cham: Springer; 2017. p. 285–90.CrossRefGoogle Scholar
  123. 123.
    Chen NC, Shauver MJ, Chung KC. Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for Dupuytren contracture. J Hand Surg Am. 2011;36(11):1826–34.e32.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    de Salas-Cansado M, Cuadros M, Arandes JM, et al. PMS11 budget impact analysis in spanish patients with Dupuytren’s contracture: fasciectomy versus collagenase clostridium histolyticum. Value Health. 2012;15(7):A441.CrossRefGoogle Scholar
  125. 125.
    Sanjuán-Cerveró R, Franco-Ferrando N, Poquet-Jornet JE, et al. Short-term cost-utility analysis of collagenase versus fasciectomy for Dupuytren contracture. In: Werker PMN, Dias J, Eaton C, et al., editors. Dupuytren disease and related diseases. The cutting edge. Cham: Springer; 2017. p. 271–5.CrossRefGoogle Scholar
  126. 126.
    Institute for Quality and Efficiency in Health Care (IQWiG). Collagenase clostridium histolyticum–Benefit assessment according to §35a social code book V. Extract of dossier assessment No. A11–27 version 1.0. January 30, 2012.Google Scholar
  127. 127.
    Horsley W. NHS North East Treatment Advisory Group. Collagenase (Xiapex®) for Dupuytren’s contracture. 2011. From www.netag.nhs.uk/files/appraisal-reports.
  128. 128.
    Inês M, Silveiro NM, Erdogan-Cifci E. Cost-minimization analysis of collagenase clostridium histolyticum compared with fasciectomy in patients with Dupuytren’s contracture in Portugal. Value Health. 2011;14(7):A310.CrossRefGoogle Scholar
  129. 129.
    de Salas-Cansado M, Cuadros M, del Cerro M, et al. Budget impact analysis in spanish patients with Dupuytren’s contracture: fasciectomy vs. collagenase clostridium histolyticum. Chir Main. 2013;32(2):68–73.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Mehta S, Belcher HJ. A single-centre cost comparison analysis of collagenase injection versus surgical fasciectomy for Dupuytren’s contracture of the hand. J Plast Reconstr Aesthet Surg. 2014;67(3):368–72.PubMedCrossRefGoogle Scholar
  131. 131.
    Neuwirth M, Binter A, Pipam W, et al. Kosteneffektivität der Behandlung von Patienten mit Dupuytren-Kontraktur mit mikrobieller collagenase clostridium histolyticum (Xiapex®) im Vergleich zur partiellen Fasziektomie in Österreich. Comparative cost effectiveness of clostridium histoliticum collagenase (Xiapex®) and partial fasciectomy for the treatment of Dupuytren’s contracture in Austria. Handchir Mikrochir Chir. 2016;48(4):233–8.CrossRefGoogle Scholar
  132. 132.
    Leskelä RL, Herse F, Torkki P, et al. Analysis of the adoption of new health technology: the case of Dupuytren’s disease. Int J Health Tech Manag. 2016;15(3):210–27.CrossRefGoogle Scholar
  133. 133.
    Meals RA, Hentz VR. Technical tips for collagenase injection treatment for Dupuytren contracture. J Hand Surg Am. 2014; 39(6):1195–200. Appendix A: instruction for care and therapy for your hand after Xiaflex injection for Dupuytren disease. J Hand Surg Am. 2014; 39(6):1200.e1–e2.CrossRefGoogle Scholar
  134. 134.
    Cheung G, Gajic T, Brown DJ. Collagenase induced syndactyly: a case report. J Hand Surg Eur. 2016;41(6):665–6.CrossRefGoogle Scholar
  135. 135.
    King ICC, Belcher HJCR. Cold intolerance following collagenase clostridium histolyticum treatment for Dupuytren contracture. J Hand Surg Am. 2014;39(4):808.PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    McKirdy SW, Jacobs N, Nassab R, et al. A retrospective review of cold intolerance following corrective surgery for Dupuytren’s disease. Hand Ther. 2007;12(2):55–9.CrossRefGoogle Scholar
  137. 137.
    Povlsen B, Singh S. Acute double flexor tendon ruptures following injection of collagenase clostridium histolyticum (Xiapex) for Dupuytren’s contracture. BMJ Case Rep. 2014.  https://doi.org/10.1136/bcr-2013-203338.
  138. 138.
    Spiers JD, Ullah A, Dias JJ. Vascular complication after collagenase injection and manipulation for Dupuytren’s contracture. J Hand Surg Eur. 2014;39(5):554–6.CrossRefGoogle Scholar
  139. 139.
    Sanjuán-Cerveró R, Poquet-Jornet JE, Carrera-Hueso FJ. Toxic dermatitis secondary to treatment with collagenase clostridium histolyticum for Dupuytren’s disease. Eur Rev Med Pharmacol Sci. 2016;20(17):3688–91.PubMedPubMedCentralGoogle Scholar
  140. 140.
    Felici N, Marcoccio I, Giunta R, et al. Dupuytren contracture recurrence project; reaching. Handchir Mikrochir Plast Chir. 2014;46(6):350–4.CrossRefPubMedGoogle Scholar
  141. 141.
    Kan HJ, Verrijp FW, Hovius ER, et al. Recurrence of Dupuytren’s contracture: a consensus-based definition. PLoS One. 2017;12(5):e0164849.  https://doi.org/10.1371/journal.pone.0164849 PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Boeckstyns M, Boyce DE, Vasenius J, et al. Recurrence rates in patients with Dupuytren’s contracture 3 years after successful treatment with collagenase clostridium histolyticum. En: Federation of European Societies for Surgery of the Hand–XVII Congress: 20-23 June 2012; Antwerp, Belgium. Ann Rheum Dis. 2012;71(Suppl 3):619. www.abstracts2view.com/eular/view.php?nu=EULAR12L_SAT0434[11/04/2014 11:13:51] Google Scholar
  143. 143.
    Akhavani MA, McMurtrie A, Webb M, et al. A review of the classification of Dupuytren’s disease. J Hand Surg Eur Vol. 2015;40(2):155–65.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Becker GW, Davis TRC. The outcome of surgical treatment for primary Dupuytren’s disease. A systematic review. J Hand Surg Eur. 2010;35(8):623–6.CrossRefGoogle Scholar
  145. 145.
    Ellis B, Bruton A. Study to compare the realibility of composite finger flexion with goniometry for measurement of range of motion in the hand. Clin Rehabil. 2002;16(5):562–70.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
    Engstrand C, Kreves B, Kvist J. Interrater reability in finger joint goniometer measurement in Dupuytren’s disease. Am J Occup Ther. 2012;66(1):98–103.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Kan HJ, Verrijp FW, Huisstede BMA, et al. The consequences of different definitions for recurrence of Dupuytren’s disease. J Plast Reconstr Aest Surg. 2013;66(1):95–103.CrossRefGoogle Scholar
  148. 148.
    Bayat A, McGrouther DA. Dupuytren’s disease. Surgery. 2006;24(11):373–5.Google Scholar
  149. 149.
    Chen CC, Bode RK. Psychometric validation of the Manual Ability Measure-36 (MAM-36) in patients with neurologic and musculoskeletal disorders. Arch Phys Med Rehabil. 2010;91(3):414–20.PubMedCrossRefPubMedCentralGoogle Scholar
  150. 150.
    Sauerland S, Lefering R, Bayer-Sandow T, et al. Fingers, hands or patients? The concept of independent observations. J Hand Surg Br. 2003;28(2):102–5.PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Mulley AC, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients’ preferences matter. Br Med J. 2012;345:e6572.CrossRefGoogle Scholar
  152. 152.
    Knobloch K, Kühn M, VogT PM. Patienten-orientierte Fragebögen als klinische Endpunke bei Morbus Dupuytren. Plast Chir. 2011;11(2):16–20.Google Scholar
  153. 153.
    Knobloch K, Kühn M, Sorg H, et al. German version of the Unité Rhumatologique des Affections de la Main (URAM) scale in Dupuytren’s disease: the need for a uniform definition of recurrence. Comment on the article by Beaudreil J, Allard A, Zerkak D, et al. Arthritis Care Res. 2011;63(10):1448–55.CrossRefGoogle Scholar
  154. 154.
    Dias JJ, Bhowal B, Wildin CJ, et al. Assessing outcome of hand disorders. Is the Patient Evaluation Measure (P.E.M.) reliable, valid, responsive and without bias? J Bone Joint Surg Br. 2001;83(2):235–40.PubMedCrossRefGoogle Scholar
  155. 155.
    Macey AC, Burke FD, Abbott K, et al. Outcomes of hand surgery. J Hand Surg Br. 1995;20(6):841–55.PubMedCrossRefGoogle Scholar
  156. 156.
    Sharma R, Dias JJ. Validity and reliability of the three generic outcomes measures for hand disorders. J Hand Surg Br. 2000;25(6):593–600.PubMedCrossRefGoogle Scholar
  157. 157.
    Chung KC, Pillsbury MS, Walters MR, et al. Radiability and validity testing of the Michigan hand outcomes questionaire. J Hand Surg Am. 1998;23(4):575–87.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Larson D. The relative responsiveness of patient-rated outcome measures in evaluating clinical change after Dupuytren’s surgery: a literature review and prospective observational pilot study. Hand Ther. 2012;17(3):52–9.CrossRefGoogle Scholar
  159. 159.
    Mohan A, Vadher J, Ismail H, et al. The Southampton Dupuytren’s scoring scheme. J Plast Surg Hand Surg. 2014;48(1):28–33.PubMedCrossRefPubMedCentralGoogle Scholar
  160. 160.
    Budd HR, Larson D, Chojnowski A, et al. The QuickDASH score: a patient-reported outcome measure for Dupuytren’s surgery. J Hand Ther. 2011;24(1):15–20.PubMedCrossRefGoogle Scholar
  161. 161.
    Mohan A, Vadher J, Ismail H, et al. The Southampton Dupuytren’s scoring scheme. J Hand Surg Eur. 2011;36(Supp 1):S62.Google Scholar
  162. 162.
    Beaudreuil J, Allard A, Zerkak D, for the URAM Study Group, et al. Unité Rhumatologique des Affections de la Main (URAM) scale: development and validation of a tool to assess Dupuytren’s disease-specific disability. Arthritis Care Res. 2011;63(10):1448–55.CrossRefGoogle Scholar
  163. 163.
    Degreef I, Verefve PB, DeSmet L. Effect of severity of Dupuytren contracture on disability. Scand J Plast Reconstr Surg Hand Surg. 2009;43(1):41–2.PubMedCrossRefGoogle Scholar
  164. 164.
    Forget NJ, Jerosch-Herold C, Shepstone L, et al. Psychometric evaluation of the Disabilities of the Arm, Shoulder and Hand (DASH) with Dupuytren’s contracture: validity evidence using Rasch modeling. BMC Musculoskelet Disord. 2014;15:361.  https://doi.org/10.1186/1471-2474-15-361.CrossRefPubMedPubMedCentralGoogle Scholar
  165. 165.
    Rodrigues JN, Zhang W, Scammell BE, et al. Validity of the disability of the arm, shoulder and hand patient-reported outcome measure (DASH) and the Quickdash when used in Dupuytren’s disease. J Hand Surg Eur. 2016;41(6):589–99.CrossRefGoogle Scholar
  166. 166.
    Żyluk A, Jagielski W. The effect of the severity of the Dupuytren’s contracture on the function of the hand before and after surgery. J Hand Surg Eur. 2007;32(3):326–9.CrossRefGoogle Scholar
  167. 167.
    Beaton DE, Wright JG, Katz JN. Development of the QuickDASH: comparison of the three-item reduction approaches. J Bone Joint Surg Am. 2005;87(5):1038–46.PubMedPubMedCentralGoogle Scholar
  168. 168.
    Rodrigues JN, Zhang W, Scammell BE, et al. What patients want from the treatment of Dupuytren’s disease–is the Unité Rhumatologique des Affectons de la Main (URAM) scale relevant? J Hand Surg Eur. 2015;40(2):150–4.CrossRefGoogle Scholar
  169. 169.
    Warwick D. Correlation of function with deformity in Dupuytren disease: the condition-specific Southampton scoring scheme outperforms the generic QuickDASH. In: Werker PMN, Dias J, Eaton C, et al., editors. Dupuytren disease and related diseases. The cutting edge. Cham: Springer; 2017. p. 199–204.CrossRefGoogle Scholar
  170. 170.
    Knoblock K, Vogt PM. Beware of the small finger and/or the proximal interphalangeal joint? Skin lacerations following collagenase injection in Dupuytren contracture. Plast Reconstr Surg. 2012;130(1):202e–4e.CrossRefGoogle Scholar
  171. 171.
    Wilburn J, McKenna SP, Perry-Hinsley D, et al. The impact of Dupuytren disease on patient activity and quality of life. J Hand Surg Am. 2013;38(6):1209–14.PubMedCrossRefGoogle Scholar
  172. 172.
    Witthaut J, Bushmakin AG, Gerber RA, et al. Determining clinically important changes in range of motion in patients with Dupuytren’s contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study. Clin Drug Investig. 2011;31(11):791–8.PubMedCrossRefGoogle Scholar
  173. 173.
    Altzieber J, Hubmer M, Parvizi D, et al. Dupuytren’s contracture: the status and impact of collagenase clostridium histolyticum in Austria. Saf Health. 2017;3:12.  https://doi.org/10.1186/s40886-017-0063-8.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • José M. Arandes-Renú
    • 1
  • Rafael Sanjuán-Cerveró
    • 2
  • Ignacio Moya-Molinas
    • 1
  1. 1.Unidad del Miembro Superior, Hospital Clinic, Universidad de BarcelonaBarcelonaSpain
  2. 2.Cirugía Ortopédica y Traumatología, Hospital de DeniaAlicanteSpain

Personalised recommendations